Sorrento Therapeutics, Inc. SRNE shares are trading higher after the company announced its STI-4398 demonstrated ability in preclinical studies to completely inhibit the Sars-Cov-2 viral infection in vitro.
Sorrento Therapeutics is a clinical-stage biopharma company that develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases.
Sorrento's shares were up 7.77% at $4.16 per share on Friday at the time of publication. The company has a 52-week high of $10.00 and a 52-week low of $1.39.
Related Links:
Sorrento Therapeutics Has $4B Coronavirus Opportunity, Analyst Says
Revisiting The Coronavirus Vaccine Race: Updates On The 10 Candidates In Clinics
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
